GlassScriptPhysician profile
Gregory T Sholeff
NPI 1104924448
$2,513.71
in general payments reported to CMS, 2019-2025
35 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $351 · 2021: $384 · 2022: $193 · 2023: $563 · 2024: $466 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372 · Education: $60.00 · Entertainment: $16.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.77 |
| Education | $60.00 |
| Entertainment | $16.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $649.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $256.14 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $191.62 | 2023-2025 | |
| Amgen INC. | $181.43 | 2020-2024 | Repatha, Otezla, Krystexxa |
| Abbott Laboratories | $141.37 | 2021-2023 | Freestyle Libre 2 |
| Abbvie INC. | $140.41 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.35 | 2019-2025 | Jardiance |
| Eisai INC. | $87.91 | 2025 | |
| Lilly USA, LLC | $78.44 | 2021-2023 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $65.74 | 2020-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $61.32 | 2022-2023 | Myrbetriq |
| Esperion Therapeutics, INC. | $58.02 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $47.83 | 2020-2021 | |
| Genzyme Corporation | $37.89 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.83 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.39 | 2025 | |
| Glaxosmithkline, LLC. | $28.44 | 2024 | Shingrix, Arexvy |
| Lucid Diagnostics INC. | $28.01 | 2023 | |
| Janssen Pharmaceuticals, INC | $27.86 | 2022-2023 | Xarelto |
| Mylan Specialty L.P. | $26.67 | 2024 | Yupelri |
| Edwards Lifesciences Corporation | $25.40 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amarin Pharma, INC. | $21.26 | 2020 | |
| Viatris Specialty LLC | $20.31 | 2025 | Yupelri |
| Boston Scientific Corporation | $19.45 | 2020 | |
| Coala Life INC | $17.82 | 2022 | |
| Medtronic, INC. | $17.50 | 2023 | Intellis Adaptivestim |
| Ethicon US, LLC | $17.19 | 2019 | |
| Gilead Sciences, INC. | $16.96 | 2021 | |
| Optos, INC. | $16.56 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Shield Therapeutics INC | $15.59 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.47 | 2020 | |
| Radius Health, INC. | $13.93 | 2023 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $12.68 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Sholeff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.